JP2020535172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535172A5 JP2020535172A5 JP2020517549A JP2020517549A JP2020535172A5 JP 2020535172 A5 JP2020535172 A5 JP 2020535172A5 JP 2020517549 A JP2020517549 A JP 2020517549A JP 2020517549 A JP2020517549 A JP 2020517549A JP 2020535172 A5 JP2020535172 A5 JP 2020535172A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound according
- compound
- treatment
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- -1 C 1- C 3 alkyl Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 17
- 230000002265 prevention Effects 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 230000003018 neuroregenerative effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1715637.3A GB201715637D0 (en) | 2017-09-27 | 2017-09-27 | SRPK1 Inhibitors |
| GB1715637.3 | 2017-09-27 | ||
| GB1810765.6 | 2018-06-29 | ||
| GBGB1810765.6A GB201810765D0 (en) | 2018-06-29 | 2018-06-29 | SRPK1 inhibitors |
| PCT/GB2018/052735 WO2019063996A1 (en) | 2017-09-27 | 2018-09-26 | INHIBITORS OF SRPK1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535172A JP2020535172A (ja) | 2020-12-03 |
| JP2020535172A5 true JP2020535172A5 (https=) | 2021-11-04 |
| JP7261793B2 JP7261793B2 (ja) | 2023-04-20 |
Family
ID=63722692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517549A Active JP7261793B2 (ja) | 2017-09-27 | 2018-09-26 | Ｓｒｐｋ１阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11420969B2 (https=) |
| EP (1) | EP3687990A1 (https=) |
| JP (1) | JP7261793B2 (https=) |
| CN (1) | CN111448193B (https=) |
| AU (1) | AU2018341084B2 (https=) |
| CA (1) | CA3077749A1 (https=) |
| WO (1) | WO2019063996A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
| GB202010829D0 (en) | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| EP4646263A1 (en) * | 2023-01-20 | 2025-11-12 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | Sprk1 inhibitors and methods of use |
| WO2025243082A2 (en) * | 2024-05-24 | 2025-11-27 | The Chinese University Of Hong Kong | Covalent protein-protein interaction inhibitor against srpks |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820178B2 (en) | 2001-08-01 | 2010-10-26 | University of Brisol | VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents |
| US7429603B2 (en) * | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
| CA2801848C (en) * | 2003-12-26 | 2015-03-31 | Masatoshi Hagiwara | Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| WO2009020198A1 (ja) | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| JP2012509306A (ja) | 2008-11-22 | 2012-04-19 | ザ ユニバーシティ オブ ブリストル | ＶＥＧＦｘｘｘｂの新規な使用 |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| ES2858511T3 (es) * | 2012-10-17 | 2021-09-30 | Exonate Ltd | Compuestos útiles para tratar neovascularización ocular |
| GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
-
2018
- 2018-09-26 CN CN201880075104.5A patent/CN111448193B/zh active Active
- 2018-09-26 AU AU2018341084A patent/AU2018341084B2/en active Active
- 2018-09-26 US US16/651,182 patent/US11420969B2/en active Active
- 2018-09-26 EP EP18782140.0A patent/EP3687990A1/en active Pending
- 2018-09-26 JP JP2020517549A patent/JP7261793B2/ja active Active
- 2018-09-26 CA CA3077749A patent/CA3077749A1/en active Pending
- 2018-09-26 WO PCT/GB2018/052735 patent/WO2019063996A1/en not_active Ceased
-
2022
- 2022-08-04 US US17/880,925 patent/US12325704B2/en active Active